Drug Trial Radar · NCT02142959
RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE
Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
187
Actual
Start
Jun 30, 2014
Primary completion
Apr 30, 2015
Study completion Apr 30, 2015
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- May 20, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Radiation dermatitis is experienced by almost all patients (up to 95%) receiving radiation therapy for cancer. Radiation dermatitis can be a serious condition because, in addition to its direct physical complications and the resulting impact on overall quality of life, it can also be a dose-limiting toxicity requiring changes to the prescribed course of radiation therapy. The most common strategy employed in an attempt to prevent or minimize radiation dermatitis involves moisturization of the irradiated area, use of a mild soap to keep the area clean, and minimizing exposure to potential mechanical irritants, such as scratching and rough clothing. However, this strategy has been shown to lack clinically significant efficacy. Consequently, there is a clinical need for new treatments that are effective in protecting against radiotherapy-induced oxidative stress and the subsequent development of radiation dermatitis. Based on data from previous studies in animals and humans, Reata believes that omaveloxolone (RTA 408) Lotion may effectively prevent and mitigate radiation dermatitis in oncology patients undergoing radiation therapy. This randomized, double-blind, vehicle-controlled, parallel-group trial will study the efficacy, tolerability and safety of two concentrations of omaveloxolone (RTA 408) Lotion (3% and 0.5%) versus vehicle in patients with breast cancer for whom radiation therapy is recommended.
Conditions
- Breast Cancer
Interventions
Omaveloxolone Lotion 0.5%Drug
Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
Omaveloxolone Lotion 3%Drug
Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
Vehicle LotionDrug
Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
3D conformal radiation therapyRadiation
45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy to the Breast Following Topical Application of Omaveloxolone Lotion or Lotion VehicleTime frame: Day 1 of radiation treatment through the last day of radiation treatment (maximum of 19 weeks), time averaged effect on radiation dermatitis reported
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers
Mesa, Arizona
St. Joseph's Hospital and Medical Center
Phoenix, Arizona
Arizona Cancer Center
Scottsdale, Arizona
University of Colorado Hospital, Dept. of Radiation Oncology
Aurora, Colorado
Norwalk Hospital
Norwalk, Connecticut
Lakeland Regional Cancer Center
Lakeland, Florida
John B. Amos Cancer Center
Columbus, Georgia
St. Vincent Anderson Regional Hospital Cancer Center
Anderson, Indiana
Parkview Research Center
Fort Wayne, Indiana
Radiation Oncology Associates - Parkview Research Center
Fort Wayne, Indiana
Northern Indiana Cancer Research Consortium
South Bend, Indiana
Willis-Knighton Cancer Center
Shreveport, Louisiana
University of Nebraska Medical Center - Eppley Cancer Center
Omaha, Nebraska
CaroMont Health Comprehensive Cancer Center
Gastonia, North Carolina
Sanford Health
Bismarck, North Dakota
St. John Health System
Tulsa, Oklahoma
Abington Memorial Hospital
Abington, Pennsylvania
Hughes Cancer Center
East Stroudsburg, Pennsylvania
Mount Nittany Medical Center
State College, Pennsylvania
AnMed Health Cancer Center
Anderson, South Carolina
21st Century Oncology - Carolina Regional Cancer Center
Myrtle Beach, South Carolina
Spartanburg Regional Medical Center - Gibbs Cancer Center
Spartanburg, South Carolina
Sanford Research/USD
Sioux Falls, South Dakota
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Cancer Care Northwest
Spokane, Washington
Mayo Clinic - LaCrosse
La Crosse, Wisconsin
Columbia St. Mary's
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.